a canine model of coronary artery occlusion.9 This finding suggested that the endothelial hyperplasia in the collateral vessels may be associated with increased production of vasodilator prostaglandins. However, indomethacin has been demonstrated to exert vasoconstrictor activity independent of its effect on cyclooxygenase. 10 Because of the widespread use of aspirin in patients with occlusive coronary artery disease, it seemed important to determine whether this agent would also impair coronary collateral blood flow. Con- sequently, the present study was carried out to examine the effect of aspirin on coronary collateral blood flow.
Methods Studies were performed in 13 adult mongrel dogs of either sex that weighed [22] [23] [24] [25] [26] [27] [28] kg and were obtained from a licensed dealer. None of these animals were used in our previous study of the effects of indomethacin on coronary collateral blood flow.9 Group 1 consisted of six animals that were used to determine the degree of cyclooxygenase blockade by measuring the response of coronary blood flow to intra-arterial arachidonic acid before and after administration of aspirin. Group 2 consisted of seven animals with chronic coronary artery occlusion that were used to examine the effect of aspirin on coronary collateral blood flow. All studies were performed in accordance with the "Position of the American Heart Association on Research Animal Use" adopted November 11, 1984 , and under the supervision of the Animal Care Committee of the University of Minnesota.
Group 1
Six adult mongrel dogs were anesthetized with sodium pentobarbital (30- infusion, hemodynamic measurements were made, and retrograde flow collections were performed. After retrograde flows returned to baseline, aspirin was administered as an intravenous bolus dose of 1 mg/kg. Hemodynamic measurements were recorded continuously, and retrograde flow measurements were obtained 30 minutes after aspirin. A second bolus dose of aspirin (14 mg/kg) was then administered intravenously. Thirty minutes after the second dose of aspirin, hemodynamic measurements were recorded, and retrograde flow collections were repeated. After completion of these measurements, intracoronary infusion of nitroglycerin and retrograde flow collection were repeated as described above.
Statistical Analysis
Heart rate and pressures were measured from the strip-chart recordings. For Figure 2 and Table 3 . During control conditions, retrograde flow ranged from 15 to 68 ml/min (average, 37±7 ml/min). Thirty minutes after low-dose aspirin (1 mg/kg i.v.), retrograde flows were decreased in every animal (mean decrease, 24±5%,p<0.03). The tendency for increased aortic pressure in conjunction with the decreased retrograde flow following low-dose aspirin resulted in a 50±15% (p<0.03) mean increase in collateral vascular resistance. Following these measurements, aspirin (15 mg/kg i.v. cumulative dose) was administered. Retrograde flows were further decreased (mean decrease, 43±10%; p<0.02) and resistance was further increased (mean increase, 100±44%, p<0.02) after high-dose aspirin.
Retrograde blood flow and nitroglycerin. To assess the reversibility of aspirin-induced collateral constriction, nitroglycerin was infused before and after aspirin administration in five animals. Hemodynamic measurements and retrograde blood flows during baseline conditions and during each nitroglycerin infusion are shown in Figure 3 and in which continuing tissue flow measured with radioactive microspheres during retrograde flow collection was found to account for <25% of total collateral flow.18 Thus, although the retrograde flow measurements obtained in the present study would slightly underestimate total collateral flow, they are representative of blood flow through epicardial coronary collateral vessels.
Effect ofAspirin on Collateral Blood Flow
We recently observed that indomethacin caused a significant decrease in coronary collateral blood flow in dogs with chronic coronary artery occlusion.9 This was an unexpected finding since cyclooxygenase blockade with indomethacin has generally been reported to have little effect on the normal coronary circulation.56 Thus, we previously found that indomethacin did not alter the basal rate of coronary blood flow, reactive hyperemia, or the increase in coronary flow that occurred during treadmill exercise.6 Because the indomethacin-induced collateral vasoconstriction was unanticipated, it seemed important to determine whether this effect would occur with a different cyclooxygenase blocker, especially since indomethacin has been reported to exert vasoconstrictor activity independent of cyclooxygenase blockade. Thus, Forman and associates10 found that indomethacin caused vasoconstriction in the atherosclerotic human coronary circulation, but pretreatment with aspirin (2,600 mg p.o.), which clearly would result in cyclooxygenase blockade, did not blunt the indomethacin-induced coronary vasoconstriction. The investigators concluded that in the atherosclerotic coronary circulation, a portion of the coronary vasoconstriction caused by indomethacin must be attributed to a mechanism other than cyclooxygenase blockade.10 In contrast to these findings in the atherosclerotic coronary circulation, in the present study aspirin caused a decrease in collateral flow comparable to that produced by indomethacin.9 These findings support the concept that it is the cyclooxygenase blockade that decreased collateral flow rather than an effect unique to indomethacin.
Effect ofAspirin on Epicardial Arteries
Because the resistance to collateral blood flow includes not only the collateral vessels themselves but also the epicardial arteries proximal to the origin of the collateral vessels, coronary artery constriction could have contributed to the observed decrease in collateral flow in response to aspirin. To determine whether cyclooxygenase blockade causes significant vasoconstriction of proximal coronary arteries, Lane and Bove19 used quantitative angiography to assess coronary artery cross-sectional area in anesthetized closed-chest dogs. These investigators found that cyclooxygenase blockade with indomethacin (5 mg/kg i.v.) caused no change in the cross-sectional area of epicardial coronary artery segments. These previous findings suggest that the decreased collateral flow observed in the present study was not the result of aspirin-induced vasoconstriction of coronary artery segments proximal to the collateral vessels.
Effect ofAspirin on Normal Zone Flow
Collateral flow can also be influenced by changes in normal zone blood flow. Thus, agents that produce vasodilation of coronary resistance vessels with increased blood flow to normal myocardial regions cause an increase in the pressure drop across the proximal coronary artery segment, thereby decreasing the pressure available at the origin of the collateral vessels (coronary steal).20 Previous studies in anesthetized animals have demonstrated that cyclooxygenase inhibitors, including aspirin, cause either no effect or slight vasoconstriction of normal coronary resistance ves- 
Mechanism ofAction ofAspirin on Collateral Vessels
Collateral vasoconstriction produced by aspirin is analogous to the vasoconstrictor activity of cyclooxygenase blockade on the ductus arteriosus and probably is mediated through inhibition of local prostanoid production.21 Vascular prostaglandin production is concentrated in endothelial cells where the principal enzymatically derived metabolite of arachidonic acid is prostacyclin.22 Prostacyclin has been shown to cause vasodilation of coronary collateral vessels,24 so inhibition of endogenous prostacyclin production could explain the present findings. Alternatively, collateral vasoconstriction could have occurred as blockade of cyclooxygenase caused arachidonic acid to be diverted from prostaglandin synthesis into the lipoxygenase pathway.25 Arachidonic acid is metabolized by lipoxygenase to form leukotrienes C4 and D4, both of which are potent vasoconstrictors.25,26 Leukotriene production occurs principally in leukocytes but has been detected in isolated canine and human coronary artery segments.2627 However, several observations suggest that increased leukotriene production was not responsible for collateral constriction in response to aspirin in the present study. First, Lane and Bove19 found that cyclooxygenase blockade with indomethacin did not cause coronary artery constriction, suggesting little activity of the leukotriene pathway in coronary arterial vessels. Second, although coronary collateral vessels show perivascular inflammation early during their development, which might enhance leukotriene production, Schaper and associates7 found that leukocyte infiltration disappears within 8 weeks after coronary occlusion. Because the present study was performed 4-6 months after coronary occlusion, leukocyte infiltration and any tendency for increased leukotriene production would have subsided by the time the study was performed. Finally, tolerance to the vasoconstricting effect of intracoronary leukotrienes has been reported to develop within 2-4 minutes,27 whereas the collateral constriction in response to aspirin was stable during the 1-hour observation period. These considerations suggest that collateral vasoconstriction produced by aspirin did not result from increased arachidonic acid shunting into the leukotriene pathway and more likely occurred as the result of interruption of endothelial prostacyclin production by the collateral vessels. Nevertheless, without measurements of prostacyclin levels, it is not possible to resolve the mechanism for aspirin-induced collateral constriction.
Early studies suggested that low-dose aspirin (1-5 mg/kg) might provide a cardioprotective platelet antiaggregatory effect without interfering with vascular prostaglandin production.1328 However, subsequent studies failed to document a dose of aspirin that exerted significant antiplatelet activity without inhibiting endothelial prostacyclin production.3 Similarly, in the present study, aspirin in a dose of 1 mg/kg caused 70% inhibition of the coronary vasodilation produced by intra-arterial administration of arachidonic acid and decreased collateral blood flow by 24±5% (p<0.03). These findings support the concept that dosages of aspirin commonly used for antiplatelet therapy cause significant impairment of vascular prostaglandin production. The duration of this impairment was not determined in the present study.
Clinical Implications
Numerous studies have reported the benefit of antiplatelet therapy in preventing myocardial infarction and reducing cardiovascular mortality in patients with a previous myocardial infarction. 2930 Despite beneficial antiplatelet effects, the present findings suggest that interruption of endothelial cyclooxygenase metabolism by aspirin has potential for adversely affecting blood flow to collateral-dependent regions of myocardium. In a study of 33 men with angiographically documentedclinically stable exertional angina pectoris, Steele et a131 examined the effects of aspirin, dipyridamole, and a combination of the two on exercise tolerance. The duration of angina-limited treadmill exercise was increased in only those individuals receiving dipyridamole alone, suggesting that any beneficial antiplatelet effect of aspirin may have been counteracted by a deleterious effect on blood flow to potentially ischemic myocardium. In patients with atherosclerotic disease undergoing diagnostic cardiac catheterization, indomethacin was reported to decrease coronary sinus blood flow and increase myocardial oxygen extraction.32,33 The reduction of coronary blood flow in response to cyclooxygen-ase blockade in patients with coronary artery disease could have resulted from either enhanced production of vasodilator prostaglandins in the diseased vessels or myocardial dependence on collateral blood flow. Unfortunately, neither study documented the extent of collateral-dependent myocardium in their subjects.
An important finding in the present study was that collateral vasoconstriction produced by aspirin could be fully reversed by nitroglycerin. Thus, if cyclooxygenase blockade did cause myocardial ischemia because of a decrease in collateral blood flow, the present data suggest that this effect could be reversed by administration of nitroglycerin. Clearly, however, these laboratory findings must be extrapolated with care to the clinical setting.
Summary
Cyclooxygenase blockade with aspirin resulted in a substantial decrease in blood flow through well-developed coronary collateral vessels. This suggests that the endothelial cell hyperplasia observed in well-developed coronary collateral vessels is associated with increased endothelial production of vasodilator prostaglandins. Vascular prostaglandin production and collateral blood flow were impaired even with aspirin doses as low as 1 mg/kg. Importantly, however, collateral vasoconstriction produced by aspirin could be completely reversed with nitroglycerin.
